Earlier this year, the DEA responded to President Biden’s directive to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act. This pivotal change, if finalized, would reclassify marijuana as a drug with moderate to low potential for dependence, strictly for medical use.
Articles Discussing Drugs & Alcohol In The Workplace.
Microdosing Psilocybin: Popular Drug Has Implications for the Workplace
This Insight discusses what psilocybin is, how it is used, and various state and local laws that either decriminalize and/or legalize its use, or make the enforcement of its illegality a low priority. This Insight also addresses some steps employers can take if employees are “microdosing” psilocybin while at work.
DEA Will Hold Public Hearing to Address Marijuana Rescheduling
The Drug Enforcement Administration announced on August 29, 2024 that it will hold a public hearing to address the proposed rescheduling of marijuana from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). The hearing will take place on December 2, 2024 at 9 am ET at
Department of Justice Publishes Notice of Proposed Rulemaking to Reschedule Marijuana to Schedule III
The Department of Justice (DOJ) published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III of the federal Controlled Substances Act (CSA) in the Federal Register on May 21, 2024. If the rule is finalized, marijuana would be considered a drug with “moderate to low potential for physical and psychological dependence” and would be available for medical use only, not legalized at the federal level.
A Continuing Discussion on the Opioid Epidemic and the Workplace – Part 4
Executive Summary: This is Part 4 of a series of Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country. Our initial Alert on June 12, 2023 outlined the big-picture issues associated with this epidemic. Our September 7, 2023 Alert (Part 1) addressed how to identify a potential addiction issue, when to engage, and how to engage on the same.
Live from Workplace Horizons 2024 — Episode 1: What Employers Need to Know About Keeping Their Workplace Safe, Drug-Free and Productive
Welcome and thank you for joining us for this special edition of We get work™, live from Jackson Lewis’ Workplace Horizons 2024 from the Lotte New York Palace in New York City and the Wynn in Las Vegas. What follows are high level conversations on conference programs and why they were important topics to present now.
DOJ Plans to Reclassify Marijuana From Schedule I to Lower-Risk Schedule III Drug
On April 30, 2024, following a months-long process, the U.S. Department of Justice (DOJ) circulated a proposal to reclassify marijuana from a Schedule I to a Schedule III controlled substance. This historic move—likely the most substantial change to federal drug policy in more than fifty years—would place marijuana amongst the
U.S. Drug Enforcement Administration Recommends Rescheduling Marijuana To Schedule III, Similar to Tylenol With Codeine
The U.S. Drug Enforcement Administration will recommend that marijuana should be rescheduled from a Schedule I drug to a Schedule III drug, according to an announcement made April 30, 2024 by the U.S. Department of Justice. This means that marijuana would be considered a drug with “moderate to low potential
Off-Duty Conduct Protections for Employees’ 4/20 Celebrations: A Look at the High Points of a Few States’ Marijuana Laws
With the arrival of the unofficial annual holiday known as “4/20,” employers can celebrate by reminding themselves of the state laws that could protect employees’ off-duty 4/20 celebrations.
A Continuing Discussion on the Opioid Epidemic in the Workplace – Part 3
Executive Summary: This is Part 3 of a series of Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country. Our initial Alert on June 12, 2023 outlined the big-picture issues associated with this epidemic. Our September 7, 2023 Alert (Part 1) addressed how to identify a potential addiction issue, when to engage, and how to engage on same. Our December 11, 2023 Alert (Part 2) focused on some of the medical issues related to addiction and why it is helpful for employers to better understand these issues when navigating an addiction scenario with an employee. This Alert (Part 3) focuses on navigating the rehabilitation process.
Dear Littler: What are the substance use concerns of workplaces past, present, and future?
Dear Littler,
I’m in charge of organizing our holiday party this year. To keep things civil, we’re limiting alcohol and reminding employees that although our state has legalized the recreational use of marijuana, there is to be no pot at the potluck. I figured now was a good
Continuing Discussion on the Opioid Epidemic in the Workplace – Part 2
Executive Summary: This is the second of multiple Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country. Our June 12, 2023 Alert outlined the big-picture issues associated with this epidemic. Our September 7, 2023 Alert (Part 1) addressed how to identify a potential addiction issue and when and how to engage on the issue. This Alert focuses on some of the medical concerns related to addiction and why it is helpful for employers to better understand these concerns when navigating an addiction scenario with an employee.
Caroline Berdzik Shares with Business Insurance the Issues Confronting Employers Regarding Making Naloxone Available in the Workplace
This year has seen the federal approval of over-the-counter availability of naloxone — commonly known as brands Narcan and Evzio — which is used to counteract opioid overdoses and considered a lifesaving medication. As such, there is a push for employers to supply naloxone as part of workplace first-aid kits.
Stocking Naloxone in the Workplace: What Employers Need to Consider
It is well known that opioid overdoses have occurred at epidemic levels in the United States for years. According to the U.S. Centers for Disease Control and Prevention (CDC), opioid overdose deaths have increased from 21,089 in 2010, to 47,600 in 2017, to more than 80,000 in 2021 and 2022.
How Much Is Too Much? Drinking, Drugs, and Trucking
“But I only had two beers.”